Stock Analiz

IQV vs MEDP stock comparison

Iqvia vs. Medpace · data as of November 13, 2026

Iqvia (IQV) has a market value of about $43.7B, Medpace (MEDP) about $18.3B. Over their latest twelve months Iqvia had revenue of $17.3B and Medpace $2.8B.

On our five checks Medpace scores higher: 3.2 out of 5 (average) against 1.6 (weak).

By area, the stronger company is Medpace on future growth; Medpace on track record; Medpace on financial health; Iqvia on shareholder returns.

Iqvia is cheaper on earnings (P/E 32.3 vs. 36.3), while Medpace grew revenue faster over five years (22.3% vs. 7.5% a year).

Iqvia leads on 12 of the compared lines and Medpace on 9.

Side by side

IQVMEDP
Size and price
Market cap$43.7B$18.3B
Share price$265.12$653.94
Score
Overall score (of 5)1.63.2
Value11
Future growth04
Track record35
Financial health14
Shareholder returns32
Valuation
P/E (TTM)32.336.3
Forward P/E19.233.6
Price / free cash flow21.027.4
Price / sales2.56.4
EV / EBITDA16.827.9
PEG0.801.14
DCF value vs. price−24%−32%
Business
Revenue$17.3B$2.8B
Net income$1.4B$518M
Free cash flow$2.1B$668M
Net margin8.1%18.2%
Gross margin (5-yr avg.)——
ROIC (5-yr avg.)8.0%41.9%
Growth
Revenue growth (1 yr)5.9%20.0%
Revenue growth (5 yrs, per year)7.5%22.3%
EPS growth (5 yrs, per year)40.5%31.8%
Balance sheet and payouts
Net cash (cash minus debt)-$14.0B—
Dividend yieldNoneNone
Shareholder yield2.9%5.0%
Analysts
Upside to average target+18%−0%
Consensus ratingStrong buynone

Highlighted = the better figure on that line. Revenue, net income and free cash flow: IQV TTM to September 30, 2026, MEDP TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Iqvia or Medpace?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Medpace scores 3.2 out of 5 and Iqvia 1.6; the table shows where each one is stronger.

Is Iqvia cheaper than Medpace?

On trailing earnings, Iqvia trades at a P/E of 32.3 and Medpace at 36.3, so Iqvia is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Iqvia or Medpace?

Over five years Medpace grew revenue about 22.3% a year and Iqvia about 7.5% a year.

Full Iqvia analysis → Full Medpace analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.